Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

video

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

Noelle V. Frey, MD, discusses the challenges of balancing the promises of chimeric antigen receptor T-cell therapy with its side effects in patients with...
video

Options for Treating the High-Risk APL Patient

Alan Burnett, MD, takes a look at the combination of ATRA + ATO + GO in high-risk acute promyelocytic leukemia (APL) patients, the complications...
video

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more...
video

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line...

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate...
video

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory...

Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...

Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.